After completing your molecule's basic benchwork and characterization, it is time to leverage powerful simulation software for in vitro-in vivo extrapolation.
Too many biotechs rely on obsolete methods when moving into in vivo studies. Without a model-informed understanding of your molecule's ADMET (absorption, distribution, metabolism, excretion, and toxicology) properties prior to pre-clinical studies, your program is at risk of:
Conjecture-based dosing strategies
Excessive animal studies
Integrating in silico advancements into your program will help you expedite your timeline for CMC (chemistry, manufacturing, and controls) and dosing strategies.
As a result, your regulatory filings will be streamlined by minimizing the amount of pre-clinical studies needed.
What would normally take several in vivo studies, can now be achieved through faster, less expensive in silico innovations.
Physiologically-based pharmacokinetic (PBPK) modeling enables decisive actions to achieve First in Human (FIH) dosing strategies and faster commercial development.
From your molecule's chemical properties, this innovative software can extrapolate in silico predictions for:
Using this information, you can make well-informed decisions on the appropriate pre-clinical animal study.
Shortening your clinical development timeline with in silico FIH dose selection and formulation optimization is possible and can improve the following:
Tissue-specific solubility (in vivo solubilities within different tissue environments)
Non-compartmental, analysis-based modeling
Algorithmic determination per species, formulation, and dosing route (oral and injectable)
A strong understanding of human ADMET properties before reaching FIH allows for effective dosing strategies and more efficient regulatory interactions.